Posting Date: July 30, 2021

Closing Date: August 9, 2021 11:30 a.m. ET

Reference Number: 21-046004

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Fetal Bovine Serum – Optima, Heat Inactivated

The HIV and AIDS Malignancy Branch (HAMB), conducts laboratory and clinical research in AIDS-related malignancies, HIV disease, viral-induced tumors, and related diseases. The mission of HAMB is to understand the pathogenesis of these diseases and to develop novel therapies for them based on this understanding. HAMB research is translational and is comprised of an integrated laboratory and clinical effort. Laboratory research is focused on developing and studying new therapies for HIV infection, on the tumors that cause HIV-associated malignancies, and on developing novel therapies for HIV-associated cancers. Clinical research is currently directed towards AIDS-related malignancies.

The National Cancer Institute plans to purchase 48 Fetal Bovine Serum – Optima, Heat Inactivated from R & D Systems. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on August 9, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

Gammaherpesviruses are associated with numerous cancers, especially in people living with HIV/AIDS. We require fetal bovine serum to culture primary cells and cell lines of gammaherpesvirus infections, in addition to patient samples that harbor bloodborne pathogens. We acquired and tested multiple lots of serum from two vendors and determined that Optima Heat Inactivated FBS was the best product to support growth of murine and human cells in our lab.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request